Zhiliang Bai

Zhiliang Bai

Auto-generated profile, based on publicly available information

Zhiliang Bai

Department of Biomedical Engineering, Yale University, New Haven, CT 06520, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2023 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
PDF file
ABAlev Baysoy
Alev Baysoy
ZBZhiliang Bai
Zhiliang Bai
RSRahul Satija
Rahul Satija
RFRong Fan
Rong Fan

13 November 2020 in Cell
Verified
Journal Article
Closed access
YLYang Liu
Yang Liu
MYMingyu Yang
Mingyu Yang
YDYanxiang Deng
Yanxiang Deng
GSGraham Su
Graham Su
AEArchibald Enninful
Archibald Enninful
RFRong Fan
Rong Fan

10 February 2022 in Science
Verified
Journal Article
Closed access
YDYanxiang Deng
Yanxiang Deng
MBMarek Bartosovic
Marek Bartosovic
PKPetra Kukanja
Petra Kukanja
DZDi Zhang
Di Zhang
YLYang Liu
Yang Liu
RFRong Fan
Rong Fan
Spatial omics emerged as a new frontier of biological and biomedical research. Here, we present spatial-CUT&Tag for spatially resolved genome-wide profiling of histone modifications by combining in situ CUT&Tag chemistry, microfluidic deterministic barcoding, and next-generation sequencing. Spatially resolved chromatin states in mouse embryos revealed tissue-type-specific epigenetic regulations in concordance with ENCODE references and provide spatial information at tissue scale. Spatial-CUT&Tag revealed epigenetic control of the cortical layer development and spatial patterning of cell types determined by histone modification in mouse brain. Single-cell epigenomes can be derived in situ by identifying 20-micrometer pixels containing only one nucleus using immunofluorescence imaging. Spatial chromatin modification profiling in tissue may offer new opportunities to study epigenetic regulation, cell function, and fate decision in normal physiology and pathogenesis.

10 June 2022 in Science Advances
Verified
Journal Article
Open access
ZBZhiliang Bai
Zhiliang Bai
SWSteven Woodhouse
Steven Woodhouse
ZZZiran Zhao
Ziran Zhao
RARahul Arya
Rahul Arya
KGKiya Govek
Kiya Govek
Jan Joseph MelenhorstJan Joseph Melenhorst
Jan Joseph Melenhorst
A notable number of acute lymphoblastic leukemia (ALL) patients develop CD19-positive relapse within 1 year after receiving chimeric antigen receptor (CAR) T cell therapy. It remains unclear if the long-term response is associated with the characteristics of CAR T cells in infusion products, hindering the identification of biomarkers to predict therapeutic outcomes. Here, we present 101,326 single-cell transcriptomes and surface protein landscape from the infusion products of 12 ALL patients. We observed substantial heterogeneity in the antigen-specific activation states, among which a deficiency of T helper 2 function was associated with CD19-positive relapse compared with durable responders (remission, >54 months). Proteomic data revealed that the frequency of early memory T cells, rather than activation or coinhibitory signatures, could distinguish the relapse. These findings were corroborated by independent functional profiling of 49 patients, and an integrative model was developed to predict the response. Our data unveil the molecular mechanisms that may inform strategies to boost specific T cell function to maintain long-term remission.

25 September 2024 in Nature
Verified
Journal Article
Open access
PDF file
BFBing Feng
Bing Feng
ZBZhiliang Bai
Zhiliang Bai
XZXiaolei Zhou
Xiaolei Zhou
YZYang Zhao
Yang Zhao
YXYu-Qing Xie
Yu-Qing Xie
LTLi Tang
Li Tang
Current cancer immunotherapy predominately focuses on eliciting type 1 immune responses fighting cancer; however, long-term complete remission remains uncommon1,2. A pivotal question arises as to whether type 2 immunity can be orchestrated alongside type 1-centric immunotherapy to achieve enduring response against cancer3,4. Here we show that an interleukin-4 fusion protein (Fc–IL-4), a typical type 2 cytokine, directly acts on CD8+ T cells and enriches functional terminally exhausted CD8+ T (CD8+ TTE) cells in the tumour. Consequently, Fc–IL-4 enhances antitumour efficacy of type 1 immunity-centric adoptive T cell transfer or immune checkpoint blockade therapies and induces durable remission across several syngeneic and xenograft tumour models. Mechanistically, we discovered that Fc–IL-4 signals through both signal transducer and activator of transcription 6 (STAT6) and mammalian target of rapamycin (mTOR) pathways, augmenting the glycolytic metabolism and the nicotinamide adenine dinucleotide (NAD) concentration of CD8+ TTE cells in a lactate dehydrogenase A-dependent manner. The metabolic modulation mediated by Fc–IL-4 is indispensable for reinvigorating intratumoural CD8+ TTE cells. These findings underscore Fc–IL-4 as a potent type 2 cytokine-based immunotherapy that synergizes effectively with type 1 immunity to elicit long-lasting responses against cancer. Our study not only sheds light on the synergy between these two types of immune responses, but also unveils an innovative strategy for advancing next-generation cancer immunotherapy by integrating type 2 immune factors.

25 September 2024 in Nature
Verified
Journal Article
Open access
PDF file
ZBZhiliang Bai
Zhiliang Bai
BFBing Feng
Bing Feng
SMSusan E. McClory
Susan E. McClory
BOBeatriz Coutinho de Oliveira
Beatriz Coutinho de Oliveira
CDCaroline Diorio
Caroline Diorio
RFRong Fan
Rong Fan
Despite a high response rate in chimeric antigen receptor (CAR) T cell therapy for acute lymphocytic leukaemia (ALL)1–3, approximately 50% of patients relapse within the first year4–6, representing an urgent question to address in the next stage of cellular immunotherapy. Here, to investigate the molecular determinants of ultralong CAR T cell persistence, we obtained a single-cell multi-omics atlas from 695,819 pre-infusion CAR T cells at the basal level or after CAR-specific stimulation from 82 paediatric patients with ALL enrolled in the first two CAR T ALL clinical trials and 6 healthy donors. We identified that elevated type 2 functionality in CAR T infusion products is significantly associated with patients maintaining a median B cell aplasia duration of 8.4 years. Analysis of ligand–receptor interactions revealed that type 2 cells regulate a dysfunctional subset to maintain whole-population homeostasis, and the addition of IL-4 during antigen-specific activation alleviates CAR T cell dysfunction while enhancing fitness at both transcriptomic and epigenomic levels. Serial proteomic profiling of sera after treatment revealed a higher level of circulating type 2 cytokines in 5-year or 8-year relapse-free responders. In a leukaemic mouse model, type 2high CAR T cell products demonstrated superior expansion and antitumour activity, particularly after leukaemia rechallenge. Restoring antitumour efficacy in type 2low CAR T cells was attainable by enhancing their type 2 functionality, either through incorporating IL-4 into the manufacturing process or by priming manufactured CAR T products with IL-4 before infusion. Our findings provide insights into the mediators of durable CAR T therapy response and suggest potential therapeutic strategies to sustain long-term remission by boosting type 2 functionality in CAR T cells.